Discriminating promiscuous from target-specific autoantibodies in COVID-19

Eur J Immunol. 2023 May;53(5):e2250210. doi: 10.1002/eji.202250210. Epub 2023 Apr 3.

Abstract

Diverse autoantibodies were suggested to contribute to severe outcomes of COVID-19, but their functional implications are largely unclear. ACE2, the SARS-CoV-2 receptor and a key regulator of blood pressure, was described to be one of many targets of autoantibodies in COVID-19. ACE2 in its soluble form (sACE2) is highly elevated in the blood of critically ill patients, raising the question of whether sACE2:spike complexes induce ACE2 reactivity. Screening 247 COVID-19 patients, we observed elevated sACE2 and anti-ACE2 IgG that were poorly correlated. Interestingly, levels of IgGs recognizing ACE2, IFNα2, and CD26 strongly correlated in severe COVID-19, with 15% of sera showing polyreactivity versus 4.1% exhibiting target-directed autoimmunity. Promiscuous autoantibodies failed to impair the activity of ACE2 and IFNα2, while only specific anti-IFNα2 IgG compromised cytokine function. Our study suggests that the detection of autoantibodies in COVID-19 is often attributed to a promiscuous reactivity, potentially misinterpreted as target-specific autoimmunity with functional impact.

Keywords: Autoantibodies; Autoimmunity; Autoreactivity; COVID-19; SARS-CoV-2.

MeSH terms

  • Autoantibodies
  • COVID-19*
  • Humans
  • Immunoglobulin G
  • Peptidyl-Dipeptidase A
  • SARS-CoV-2

Substances

  • Autoantibodies
  • Peptidyl-Dipeptidase A
  • Immunoglobulin G

Associated data

  • DRKS/DRKS00021688